

**ASX/Media Release**

**11 May 2018**

**Results of General Meeting**

**Perth 11 May 2018:** Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that a General Meeting of the Company was held today, 11 May 2018. All resolutions put to the meeting were passed on a show of hands. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out below:

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Ratification of issue of Shares to various sophisticated and professional investors under ASX Listing Rule 7.1	172,169,360	2,066,878	1,696,176	4,891,601
2	Ratification of issue of Shares to various sophisticated and professional investors under ASX Listing Rule 7.1A	177,010,961	941,878	1,696,176	1,175,000

**About Botanix Pharmaceuticals**

Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy in 1H 2017 and plans to progress the development of its pipeline of other Permetrex enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit [www.botanixpharma.com](http://www.botanixpharma.com) or follow us on Twitter @Botanixpharma.

**For more information, please contact:**

**General enquiries**

Matt Callahan  
Botanix Pharmaceuticals Ltd  
Executive Director  
P: +1 215 767 4184  
E: [mcallahan@botanixpharma.com](mailto:mcallahan@botanixpharma.com)

**Investor Relations**

Joel Seah  
Vesparum Capital  
P: +61 3 8582 4800  
E: [botanixpharma@vesparum.com](mailto:botanixpharma@vesparum.com)

**Media enquiries**

Julia Maguire  
The Capital Network  
P: +61 419 815 386  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)